Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-21

Clinical Trial Update: Study to Assess the Efficacy and Safety of Raxone in LHON Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update for Raxone in Leber's Hereditary Optic Neuropathy (LHON) has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Raxone (idebenone)

Snippet

Sponsor: Santhera Pharmaceuticals | Conditions: Leber's Hereditary Optic Neuropathy (LHON) | Phase 4 | Status: COMPLETED | Results posted: 2023-04-21